I was really glad to see the below post from options4u since i believe this to be true ....many are near "brain washed" with the common path for successful drugs and not envisioning what the unique characteristics of AVXL will be , if a success...... For starters the drug would sell itself almost....if it works what doctor would not know about it and prescribe it?...... That said IMO a partner would reduce a P3 trial approval likely ....but on the other hand if AVXL got the extremely rare BT in 90 days like discussed on this board below, ... would final gov approval even be an issue, and therefore almost no reason to partner.... Last thought is that where options4u stats 60% to BP in a partner deal ...I think Missling is too smart for this...my hope, if we seek a partner, would be 25% BP - 75% AVXL..and the logic for them accepting this would be the likely fairly small P3 and the ease of marketing... If the market is potentially 65 B for AD alone .... 25% interest of a simple but very large opportunity is very attractive for partners...